These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37871300)

  • 1. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
    Hill BT; Ma S; Zent CS; Baran AM; Wallace DS; Advani A; Winter A; Winter J; Gordan L; Karmali R; Liesveld JL; Mulford DA; Rowland C; Bui A; Sportelli P; Miskin HP; Weiss MS; Friedberg JW; Barr PM
    Blood Adv; 2024 Jan; 8(2):378-387. PubMed ID: 37871300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
    Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
    Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
    JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
    Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
    Siddiqi T; Maloney DG; Kenderian SS; Brander DM; Dorritie K; Soumerai J; Riedell PA; Shah NN; Nath R; Fakhri B; Stephens DM; Ma S; Feldman T; Solomon SR; Schuster SJ; Perna SK; Tuazon SA; Ou SS; Papp E; Peiser L; Chen Y; Wierda WG
    Lancet; 2023 Aug; 402(10402):641-654. PubMed ID: 37295445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
    Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Flinn IW; Gribben JG; Dyer MJS; Wierda W; Maris MB; Furman RR; Hillmen P; Rogers KA; Iyer SP; Quillet-Mary A; Ysebaert L; Walter HS; Verdugo M; Klein C; Huang H; Jiang Y; Lozanski G; Pignataro DS; Humphrey K; Mobasher M; Kipps TJ
    Blood; 2019 Jun; 133(26):2765-2775. PubMed ID: 30862645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
    Tang X; Zou W; Peng P; Bai Y
    Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
    Guru Murthy GS; Atallah E
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):346-350. PubMed ID: 37363977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia.
    Lovell AR; Sawyers J; Bose P
    Expert Opin Pharmacother; 2023; 24(11):1307-1316. PubMed ID: 37226798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
    J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.